

<b>INFORMATION DISCLOSURE STATEMENT</b>	Docket No.	27693-01009	Serial No:	<b>09/ 911,692</b>
	Inventor(s):	D.R. ANDERSON	Examiner:	R. Schwadron
	Filed:	25 July 2001	Art Unit:	1644

### U.S. PATENT DOCUMENTS



INITIAL	INDEX	DOCUMENT	DATE	NAME	CLASS	SUB.	FILING DATE
M	C1	2006/ 0034835 A1	16 Feb 06	Adams	—	—	

### FOREIGN PATENT DOCUMENTS


INITIAL	INDEX	DOCUMENT	DATE	COUNTRY	CLASS	SUB.	TRANSLATION
							YES NO
W	C2	2004/ 056312	08 Jul 04	WO	—	—	

### OTHER DOCUMENTS

INITIAL	INDEX	CITATION
dk	C3	Lowman, H.B. Slides presented at IBC Antibody Engineering Conference, 2 December 2003. Differential Activities in a Series of Humanized Anti-CD20 Antibodies.
w	C4	Polyak, M.J., et al. (2002) <i>Blood</i> 99: 3256-62. Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure.

EXAMINER		
Initial if a citation is considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.		
Form PTO-1449 (modified)		SHEET 1 OF 1

INFORMATION DISCLOSURE STATEMENT	Docket No.	27693-01009	Application No.	09/911,692
	Applicant(s):	ANDERSON, Darrell A.	Examiner:	SCHWADRON, Ronald B.
	Filing Date:	7/25/2001	Group Art Unit:	1644




**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

✓35	B1	Chinn, et al. "Production and characterization of radiolabeled anti-CD20 monoclonal antibody: potential application to treatment of B-cell lymphoma." Proceedings of the American Medical Association for Cancer Research, Volume 33, Abstract 2012, p. 337, 1992.
	B2	Classon, et al. "The Primary Structure of the Human Leukocyte Antigen CD37, A Species Homologue of the Rat MRC OC-44 Antigen." The Journal of Experimental Medicine, Volume 169, No. 4, pp. 1497-1502, 1989.
	B3	DeNardo, et al. "Requirements for a Treatment Plan in System for Radioimmunotherapy." International Journal of Radiation Oncology Biology Physics, Volume 11, Number 2, pp. 335-348, 1985.
	B4	Kaminski, et al. "Radioimmunotherapy (RIT) of Refractory B-Cell Lymphoma with 131-I-Anti-B1 (Anti-CD20) Antibody: Promising Early Results Using Non-Marrow Ablative Radiation Doses." Blood, Abstract 161, p. 162,
	B5	Langmuir, "Radiommunotherapy: Clinical Results and Dosimetric Considerations." Nuclear Medicine and Biology, Volume 19, Number 2, pp. 213-225, 1992.
	B6	Larson, et al. "Comparison of Bone Marrow Dosimetry and Toxic Effect of High Dose <sup>131</sup> I-labeled Monoclonal Antibodies Administered to Man." Nuclear Medicine and Biology, Volume 16, No. 2, pp.153-158, 1989.
	B7	Leichner, et al. "Tumor dosimetry in radioimmunotherapy: Methods of calculation for beta particles." Medical Physics, Volume 20, Number 2, Pt.2, pp. 529-534, 1993
	B8	Leichner, et al. "Dosimetry and Treatment Planning in Radioimmunotherapy." Frontiers of Radiation Therapy and Oncology, Vol. 24, pp. 109-120, 1990.
	B9	Link, et al. "A Unique Antigen on Mature B-Cells Defined by a Monoclonal Antibody." The Journal of Immunology, Vol. 137, No. 9, pp. 3013-3018, 1986.
	B10	Macey, et al. "A Treatment Planning Program for Radioimmunotherapy" Frontiers of Radiation Therapy and Oncology, Vol. 24, pp. 123-131, 1990.
✓	B11	Meredith, et al. "Dose Fractionation of Radiolabeled Antibodies in Patients with Metastatic Colon Cancer." Journal of Nuclear Medicine, Volume 33, Number 9, pp. 1648-1653, 1992.

EXAMINER	<i>[Signature]</i>	DATE CONSIDERED	<i>8/31/01</i>
<b>EXAMINER:</b> Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			
Form PTO-A820 (also form PTO-1449)		SHEET 1 OF 2	

*8/31/01*



<b>INFORMATION DISCLOSURE STATEMENT</b>	<b>Docket No.</b> 27693-01009	<b>Application No.</b> 09/911,692
	<b>Applicant(s):</b> ANDERSON, Darrell A.	<b>Examiner:</b> SCHWADRON, Ronald B.
	<b>Filing Date:</b> 7/25/2001	<b>Group Art Unit:</b> 1644

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

✓ M/S	B12	Parker, et al. "Radioimmunotherapy of Human B-Cell Lymphoma with <sup>90</sup> Y-conjugated Antiidiotype Monoclonal Antibody." Cancer Research, Volume 50, No. 3, pp. 1022s-1028s, 1990.
	B13	Pearson, et al. "Enhanced Therapeutic Efficacy of an Immunotoxin in combination with Chemotherapy against an Intraperitoneal Human Tumor Xenograft in Athymic Mice." Cancer Research Volume 49, No. 18, pp. 4990-4995, 1989.
	B14	Press, et al. "Endocytosis and Degradation of Monoclonal of Antibodies Targeting Human B-Cell Malignancies" Cancer Research, Volume 49, No. 17, pp. 4906-4912, 1989.
	B15	Press, et al. "Radiolabeled Antibody Therapy of Human B Cell Lymphomas." Immunobiology of Proteins and Peptides VI, Volume 303, pp. 91-96, 1991.
	B16	Securities and Exchange Commission, Form S-1 Registration Statement, Filed 1991, IDEC Pharmaceuticals
	B17	Senter, Peter D. "Activation of prodrugs by antibody-enzyme conjugates: a new approach to cancer therapy." The FASEB Journal, Vol. 4. pp. 188-193, 1990.
	B18	Senter, et al. "Activation of Prodrugs by Antibody-Enzyme Conjugates" Immunobiology of Proteins and Peptides VI, Volume 303, pp. 97-105, 1991.
	B19	Schwartz-Albiez, et al. "The B Cell-Associated CD37 Antigen (gp40-52) Structure and Subcellular Expression of an Extensively Glycosylated Glycoprotein." The Journal of Immunology, Vol. 140, No. 3, pp. 905-914, 1988.
	B20	Sharkey, et al. "Biological Considerations for Radioimmunotherapy." Cancer Research, Volume 50, No. 3, pp. 964s-969s, pp. 1990.
	B21	Stewart, et al. "Intraperitoneal <sup>131</sup> I- And <sup>90</sup> Y-Labelled Monoclonal Antibodies for Ovarian Cancer: Pharmacokinetics and Normal Tissue Dosimetry." International Journal of Cancer, Supplement 3, pp. 71-76, 1988.
	B22	Uckun, et al. "Combined Ex Vivo Treatment with Immunotoxins and Mafosfamid: A Novel Immunochemotherapeutic Approach for Elimination of Neoplastic T Cells from Autologous Marrow Grafts." The Journal of Immunology, Vol. 134, No. 5, pp. 3504-3515, 1985.
	B23	Uckun, et al. "Increased Efficiency in Selective Elimination of Leukemia Cells by a Combination of a Stable Derivative of Cyclophosphamide and a Human B-Cell-specific Immunotoxin Containing Pokeweed Antiviral Protein." Cancer Research , Volume 45, No. 1, pp. 69-75, 1985.
✓	B24	Yokota, et al. "Synergistic Potentiation of in Vivo Antitumor Activity of Anti-Human T-Leukemia Immunotoxins by Recombinant $\alpha$ -Interferon and Daunorubicin." Cancer Research, Volume 50, No. 1, pp. 32-37, 1990.

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO-A820 (also form PTO-1449)	
SHEET 2 OF 2	

<b>INFORMATION DISCLOSURE STATEMENT</b> <del>Patent &amp; Trademark Office</del> SEP 8 0 2005	Docket No.	27693-1009	Application No. 09/911,692
	Applicant(s):	ANDERSON, Darrell R.	Examiner: <b>SCHWADRON, Ronald B.</b>
	Filing Date:	7/25/2001	Group Art Unit: 1644

### U.S. PATENT DOCUMENTS

Examiner Initial	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
MJ	A1	4,975,278	12/4/1990	Senter et al.			
	A2	5,677,180	10/14/1997	Robinson et al.			
	A3	5,686,072	11/11/1997	Uhr et al.			
	A4	5,693,780	12/2/1997	Newman et al.			
	A5	5,721,108	2/24/1998	Robinson et al.			
	A6	5,843,398	12/1/1998	Kaminski et al.			
	A7	6,015,542	1/18/2000	Kaminski et al.			
	A8	6,090,365	7/18/2000	Kaminski et al.			
	A9	6,120,767	9/19/2000	Robinson et al.			
	A10	6,287,537	9/11/2001	Kaminski et al.			
	A11	6,565,827	5/20/2003	Kaminski et al.			
	A12	6,652,852	11/25/2003	Robinson, et al.			
	A13	6,893,625	5/17/2005	Robinson et al.			
	A14	2002-0009444	1/24/2002	Grillo-Lopez			
	A15	2002-0197255	12/26/2002	Anderson et al.			
	A16	2003-0021781	1/30/2003	Anderson et al.			
	A17	2003-0026804	2/24/2003	Grillo-Lopez			
	A18	2003-0082172	5/1/2003	Anderson et al.			
	A19	2003-0147885	8/7/2005	Anderson et al.			
	A20	2003-0206903	11/6/2003	Grillo-Lopez			
	A21	2004-0213784	10/28/2004	Grilo-Lopez et al.			
	A22	2005-0163708	7/28/2005	Robinson et al.			
	A23	2005-0186205	8/25/2005	Anderson et al.			

### FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
MJ	A24	WO 91/04320	4/4/1991	WO	—	—		X
JK	A25	WO 93/02180	2/4/1993	WO	—	—		X

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO-A820 (also form PTO-1449)	
SHEET 1 OF 3	

8/31/06



INFORMATION DISCLOSURE STATEMENT	Docket No. 27693-1009	Application No. 09/911,692
	Applicant(s): ANDERSON, Darrell R.	Examiner: SCHWADRON, Ronald B.
	Filing Date: 7/25/2001	Group Art Unit: 1644

OTHER DOCUMENTS (*Including Author, Title, Date, Pertinent Pages, Etc.*)

✓	A26	Badger, et al. "Experimental Radioimmunotherapy of Murine Lymphoma with <sup>131</sup> I-labeled Anti-T-Cell Antibodies." Cancer Research, 46, pp. 6223-6228, 1986.
✓	A27	Buchsbaum, et al. "Improved Delivery of Radiolabeled Anti-B1 Monoclonal Antibody to Raji Lymphoma Xenografts by Predosing with Unlabeled Anti-B1 Monoclonal Antibody." Cancer Research; 52, pp. 637-642, 1992.
	A28	Biogen Idee v. Corixa Corporation, Case No. 01-1637-IEG [Doc. Nos. 635, 662, 486] (S.D. California, January 22, 2004). <i>already of record</i>
✓	A29	Chen, et al. "Tumor Idiotype Vaccines. VI. Synergistic Anti-Tumor Effects with Combined "Internal Image" Anti-Idiotypes and Chemotherapy." Journal of Immunology, 143, pp. 1053-1057, No. 3, 1989.
	A30	Clark et al. "Role of the Bp35 cell surface polypeptide in human B-cell activation" Vol. 82; pp. 1776-1770, 1985
	A31	Clark, et al. "Phase I Evaluation of the Anti-Bp35 Antibody Induces Human B Cell Proliferation: Implications for In Vivo Immunotherapy." Journal Cellular Biochemistry Supp. 9A, p. 63, 1985
↓	A32	DeNardo, et al. "Fractionated Radioimmunotherapy of B-Cell Malignancies with <sup>131</sup> I-Lym-1." Cancer Research (Suppl.) 50, pp. 1014s-1016s, 1990.
	A33	Idée Pharmaceuticals v. Corixa Corporation, Case No. 01-1637-IEG [Doc. Nos. 486, 584] (S.D. California, October 14, 2003). <i>already of record</i>
✓	A34	Kaminski, et al. "Initial Clinical Radioimmunotherapy Results with <sup>131</sup> I-Anti-B1 (Anti-CD20) in Refractory B-Cell Lymphoma." Antibody Immunoconjugates, and Radiopharmaceuticals Vol. 5, No. 3 p. 345, 1992
	A35	Kaminski, et al. " <sup>131</sup> I Anti-B1: Initial Clinical Evaluation in B-Cell Lymphoma." Third Conference on Rid and Rit of Cancer, Abstract. No. 144, 1990.
	A36	Langmuir, "Radioimmunotherapy: Clinical Results and Dosimetric Considerations." Nuclear Medicine Biology Vol. 19, No. 2, pp. 213-225, 1992.
	A37	Levy, et al. "Tumor Therapy with Monoclonal Antibodies." Federation Proceedings 42:9 pp. 2650-2656, 1983
	A38	Macklis, et al. "Radiobiologic Studies of Low-Dose-Rate <sup>90</sup> Y-Lymphoma Therapy." Cancer Supplement, Vol. 73, No. 3, pp. 966-973, 1994.
↑	A39	Maloney, et al. "The Anti-Tumor effect of Monoclonal Anti-CD20 Antibody mAB) Therapy Includes Direct Anti-Proliferative Activity and Production of Apoptosis in CD20 Positive Non-Hodgkin's Lymphoma (NHL) Cell Lines." Interferon and Chronic Myelogenous Leukemia." Fred Hutchinson Cancer Research & University of Washington, 637a, p. 2535

EXAMINER	<i>[Signature]</i>	DATE CONSIDERED	8/31/01
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			
Form PTO-A820 (also form PTO-1449)		SHEET 2 OF 3	



INFORMATION DISCLOSURE STATEMENT	Docket No. 27693-1009	Application No. 09/911,692
	Applicant(s): ANDERSON, Darrell R.	Examiner: SCHWADRON, Ronald B.
	Filing Date: 7/25/2001	Group Art Unit: 1644


**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

(✓)	A40	Maloney, et al. "Monoclonal Anti-Idiotype Antibody Therapy of B-Cell Lymphoma: The Addition of a Short Course of Chemotherapy Does Not Interfere with the Antitumor Effect Nor Prevent the Emergence of Idiotype-Negative Variant Cells." Blood, Vol. 80, No. 6, pp. 1502-1510, 1992.
	A41	Masucci, et al. "Chemotherapy and Immunotherapy of Colorectal Cancer." Medical Oncology Tumor Pharmacother Vol. 8, No. 3, pp. 207-220, 1991.
	A42	Nadler, et al. "A Unique Cell Surface Antigen Identifying Lymphoid Malignancies of B Cell Origin." Journal of Clinical Investigative, Vol. 67, pp. 134-140, 1981.
	A43	Reilly, "Radioimmunotherapy of malignancies." Clinical Pharmacy, Vol. 10, pp. 359-375, 1991.
	A44	Press, et al. Scientific Proceedings, ASCO, Abstract No. 864, 1986.
	A45	See-Lasley, et al. "HODGKIN'S DISEASE AND NON-HODGKIN'S LYMPHOMA Nitrogen mustard, vincristine (Oncovin), procarbazine, and prednisone (MOPP)." Manual of Oncology Therapeutics, C.V. Mosby Company, pp. 44-71, 1981
	A46	Senter, et al. "Enhancement of the <i>in vitro</i> and <i>in vivo</i> Antitumor Activities of Phosphorylated Mitomycin C and Etoposide Derivatives by Monoclonal Antibody-Alkaline Phosphatase Conjugates." Cancer Research 49, pp. 5789-5792, 1989.
(✓)	A47	Stashenko, et al. "Characterization of Human B Lymphocyte-Specific Antigen." The Journal of Immunology Vol. 125, No. 4, pp. 1678-1685, 1960.

EXAMINER		DATE CONSIDERED	8/31/06
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			
Form PTO-A820 (also form PTO-1449)		SHEET 3 OF 3	


MAY 27 2004  
U.S. PATENT & TRADEMARK OFFICE

FORM PTO-1449 (modified) To: U.S. Department of Commerce (PW FORM PAT-1449) Patent and Trademark Office					Atty. Dkt. No.	M#	Client Ref.
						0280646	1992-30-0029CP1C3
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>					Applicant: ANDERSON et al.		
					Appln. No.: 09/911,692		
					Filing Date: July 25, 2001		
Date: May 27, 2004		Page <b>1</b> of <b>1</b>	Examiner: Schwadron, R. Group Art Unit: 1644				
<b>U.S. PATENT DOCUMENTS</b>							
Examiner's Initials*		Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date
	AR						
	BR						
	CR						
	DR						
	ER						
	FR						
	GR						
	HR						
<b>FOREIGN PATENT DOCUMENTS</b>							
		Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract	Translation Readily Available
	IR						
	JR						
	KR						
	LR						
	MR						
	NR						
	OR						
	PR						
<b>OTHER</b>							
<i>W</i> <i>S</i>	QR	<i>Idec Pharmaceuticals v. Corixa Corp., Case No. 01-1637-IEG [Doc. Nos. 486, 584] (S.D. Cal. Oct. 14, 2003).</i>					
<i>W</i> <i>R</i>	RR	<i>Biogen Idec v. Corixa Corp., Case No. 01-1637-IEG [Doc. Nos. 635, 662, 486] (S.D. Cal. Jan. 22, 2004).</i>					
	SR						
	TR						
	UR						
	VR						
	WR						
	XR						
	YR						
	ZR						
Examiner		Date Considered: <i>8/31/04</i>					
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.							

FORM PTO-1449 (modified) To: U.S. Department of Commerce (PW FORM PAT-1449) Patent and Trademark Office					Atty. Dkt. No.	M#	Client Ref.
						0280646	1992-30-0029CP1C3
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  					Applicant: ANDERSON et al.		
					Appln. No.: 09/911,692		
					Filing Date: July 25, 2001		
					Examiner: Schwadron, R. Group Art Unit: 1644		
<b>U.S. PATENT DOCUMENTS</b>							
Examiner's Initials*		Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date
AB	AR	5,595,721	01/1997	KAMINSKI	—	—	
	BR	5,439,665	08/1995	HANSEN	—	—	
	CR	RE 38,008	02/2003	ABRAMS	—	—	
	DR	5,736,137	04/1998	ANDERSON	—	—	
	ER	5,776,456	07/1998	ANDERSON	—	—	
	FR	5,843,439	12/1998	ANDERSON	—	—	
	GR	6,399,061	06/2002	ANDERSON	—	—	
	HR	6,682,734	01/2004	ANDERSON	—	—	
<b>FOREIGN PATENT DOCUMENTS</b>							
		Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract	Translation Readily Available
MA	IR	WO 94/11026	05/1994	PCT	ANDERSON		
	JR						
	KR						
	LR						
	MR						
<b>OTHER</b>							
AB	NR	Grossbard M.L., et al., "Monoclonal antibody-based therapies of leukemia and lymphoma," <i>Blood</i> , 1992, 80:863-878.					
	OR	Tedder T.F., et al., "Antibodies reactive with the B1 molecule inhibit cell cycle progression but not activation of human B lymphocytes," <i>Eur J Immunol</i> , 1986, 16(8):881-87.					
	PR	Tedder T.F., et al., "Cloning of a complementary DNA encoding a new mouse B lymphocyte differentiation antigen, homologous to the human B1 (CD20) antigen, and localization of the gene to chromosome 19," <i>J Immunol</i> , 1988, 141(12):4388-94.					
	QR						
	RR						
	SR						
	TR						
	UR						
Examiner				Date Considered: 8/31/06			

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 (modified)  
To: U.S. Department of Commerce  
(PW FORM PAT-1449)  
Patent and Trademark Office



Atty. Dkt. No.	M#	Client Ref.
	0280646	1992-30-0029CP1C3

Applicant: ANDERSON et al.

Appln. No.: 09/911,692

Filing Date: July 17, 2001

Date: November 21, 2003

Page **1** of **1**

Examiner: Unassigned Group Art Unit: 1644

#### U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date
MB	AR 6,183,744 B1	02/2001	GOLDENBERG	—	—	
WB	BR 6,306,393 B1	10/2001	GOLDENBERG	—	—	
CR						
DR						
ER						
FR						

#### FOREIGN PATENT DOCUMENTS

	Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract	Translation Readily Available
GR						
HR						
IR						
JR						
KR						
LR						

#### OTHER

MM	MR	Kaminski, et al., "Radioimmunotherapy of Advanced B-Cell Lymphoma with Non Bone Marrow Ablative Doses of 131-I MB-1 Antibody," 1990, <i>Antibody Immunoconjugates, and Radiopharmaceuticals</i> , Vol. 3, No. 1, Abstract No. 83.
	NR	Kaminski, et al., "Radioimmundetection (RID) and Non Marrow Ablative Radioimmunotherapy (RIT) of B-Cell Lymphoma With 131-I MB-1 Antibody," 1990, <i>Proceedings of ASCO</i> , Vol. 9, Abstract No. 1051.
	OR	Wahl, et al., "Radioimmunotherapy of B-Cell Lymphoma with I131 MB-1 Monoclonal Antibody," <i>The Journal of Nuclear Medicine: Proceedings of the 37<sup>th</sup> Annual Meeting</i> , p. 852, Abstract No. 622.
	PR	Kaminski, et al., "Phase I Trial Results of 131-I MB-1 Antibody Radioimmunotherapy (RAIT) of B-Cell Lymphoma," 1990, <i>Antibody Immunoconjugates, and Radiopharmaceuticals</i> , Vol. 4, No. 1, p. 36, Abstract No. 66.
	QR	Kaminski, et al., "Phase I Evaluation of 131-I MB-1 Antibody Radioimmunotherapy (RIT) of B-Cell Lymphoma," 1990, <i>Blood</i> , Vol. 76, No. 10, p. 355a, Abstract No. 1409.
	RR	Kaminski, et al., "Imaging, Dosimetry, and Radioimmunotherapy With Iodine 131-Labeled Anti-CD37 Antibody in B-Cell Lymphoma," 1992, <i>Journal of Clinical Oncology</i> , Vol. 10, No. 11, pp.1696-1711.
	SR	
	TR	
	UR	
	VR	


Examiner

Date Considered:

8/31/06

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 (modified)  
 To: U.S. Department of Commerce  
 (PW FORM PAT-1449)  
 Patent and Trademark Office



Atty. Dkt. No.	M#	Client Ref.
	037003-0280646	1992-30-0029CP1C3
Applicant: Anderson, et al.		
Appln. No.: 09/911,692		
Filing Date: July 25, 2001		
Date: October 21, 2003	Page 1 of 3	Examiner: Schwadron, R. Group Art Unit: 1644

### INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date: October 21, 2003

Page 1 of 3

#### U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
RB	AR 5,500,362	03/1996	Robinson, et al.	435	7.23	
WJ	BR 5,648,267	07/1997	Reff	435	320.1	
CR						

#### FOREIGN PATENT DOCUMENTS

	Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract		Translation Readily Available	
					Enclosed	No	Enclos	No
WJS	DR 0 125 023 A1	11/1984	EP	Cabilly, et al.				
	ER 0 125 023 B1	11/1984	EP	Cabilly, et al.				
	FR 0 125 023 B2	03/2002	EP	Cabilly, et al.				
	GR 0 173 494 A2	03/1986	EP	Morrison, et al.				
	HR 0 274 394 A2	07/1988	EP	Robinson, et al.				
	IR 0 274 394 A3	07/1988	EP	Robinson, et al.				
	JR 0 451 216 B1	01/1996	EP	Queen, et al.				
	KR 0 682 040 A1	11/1995	EP	Queen, et al.				
	LR 0 682 040 B1	11/1995	EP	Queen, et al.				
	MR WO 88/04936	07/1988	WO	Robinson, et al.				
↓	NR WO 92/07466	05/1992	WO	Hellström, et al.				

#### OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

WJS	Adams, R.A. et al., Direct implantation and serial transplantation of human acute lymphoblastic leukemia in hamsters, SB-2, Can Res 28:1121-1125 (1968).	
	Adams, Richard, Formal Discussion: The role of transplantation in the experimental investigation of human leukemia and lymphoma, Can. Res. 27:2479-2482 (1967).	
	Anderson, K.C., et al., Hematologic engraftment and immune reconstitution posttransplantation with anti-B1 purged autologous bone marrow, Blood 69(2):597-604 (1987)	
	Anderson, D.R., et al., Immunoreactivity and effector function associated with a chimeric anti-CD20 antibody, The Second Annual IBC International Conference on Antibody Engineering, Dec. 16-18, 1991.	
	Anderson, K.C., et al., Expression of human B cell-associated antigens on leukemias and lymphomas: A model of human B cell differentiation, Blood 63(6):1424-1433 (1984)	
	Appelbaum, F.R., Radiolabeled Monoclonal Antibodies in the Treatment of Non-Hodgkin's Lymphoma. Hem. Onc. Clinics of N.A. 5(5):1013-1025 (1991).	
	Armitage, J.O. et al., Predicting therapeutic outcome in patients with diffuse histiocytic lymphoma treated with cyclophosphamide, Adriamycin, vincristine and prednisone (CHOP), Cancer 50:1695 (1982).	
↓	Bhan, A.K., et al., Stages of B cell differentiation in human lymphoid tissue, J. Exp. Med., 154:737-749 (1981)	

M L

8/31/06

102

C103

OCT 21 2003

PATENT & TRADEMARK OFFICE

	Boulian, G.L. et al., Production of functional chimaeric mouse/human antibody, <i>Nature</i> 312:643 (December 1984).		
	Brunner, K.T. et al., Quantitative assay of the lytic action of immune lymphoid cells on <sup>51</sup> Cr-labeled allogeneic target cells <i>in vitro</i> ; inhibition by isoantibody and drugs, <i>Immunology</i> 14:181-189 (1968).		
	Buchsbaum, D.J., et al., A comparison of <sup>131</sup> I-labeled monoclonal antibody 17-1A treatment to external beam irradiation on the growth of LS174T human colon carcinoma xenografts, <i>Int. J. Radiation Oncology Biol. Phys.</i> , 18:1033-1041 (1990)		
	Buchsbaum, D.J., et al., Comparative binding and preclinical localization and therapy studies with radiolabeled human chimeric and murine 17-1A monoclonal antibodies, <i>Cancer Research (Suppl.)</i> 50:993s-999s (1990)		
	Buchsbaum, D.J., et al., Comparison of <sup>131</sup> I- and <sup>90</sup> Y-labeled monoclonal antibody 17-1A for treatment of human colon cancer xenografts, <i>Int. J. Radiation Oncology Biol. Phys.</i> 25:629-638 (1993)		
	Calvert, J.E., et al., Cellular events in the differentiation of antibody-secreting cells, <i>Seminars in Hematology</i> , 21(4):226-243 (1984)		
	Chomczynski, P. et al., Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction, <i>Anal. Biochem.</i> 162:156-159 (1987).		
	Clark, E.A., et al., Role of the Bp35 cell surface polypeptide in human B-cell activation, <i>Proc. Natl. Acad. Sci. USA</i> , 82:1766-1770 (1985)		
	Cope, Antibody shows promise in treating B-cell lymphoma, <i>Oncology</i> , 8(4):100 (1994)		
	DeNardo, S.J., et al., Pilot studies of radioimmunotherapy of B cell lymphoma and leukemia using I-131 Lym-1 monoclonal antibody, <i>Antibody, Immunoconjugates, and Radiopharmaceuticals</i> , 1(1):17-33 (1988)		
	DeNardo, S.J., et al., The biologic window for chimeric L6 radioimmunotherapy, <i>Cancer</i> 73(3):1023-32 (1994)		
	Dickson, Scientists produce chimeric monoclonal abs, <i>Genetic Engineering News</i> 5/3 (March 1985).		
	Eary, J.F. et al, Imaging and Treatment of B-Cell Lymphoma, <i>J. Nuc. Med.</i> 31/8:1257-1268 (1990).		
	Einfeld, D.A. et al., Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains, <i>EMBO</i> 7:711 (1988)		
	Golay, J.T., et al., The CD20 (Bp35) antigen is involved in activation of B cells from the G <sub>0</sub> to the G <sub>1</sub> phase of the cell cycle, <i>J. Immunology</i> 135(6):3795-3801 (1985)		
	Goldenberg, D.M. et al., Targeting, dosimetry and radioimmunotherapy of B-Cell lymphomas with iodine-131-labeled LL2 monoclonal antibody, <i>J. Clin. Onc.</i> 9/4:548-564 (1991).		
	Greenberger, J.S., et al., Effects of monoclonal antibody and complement treatment of human marrow on hematopoiesis in continuous bone marrow culture, <i>Cancer Research</i> 45:758-767 (1985)		
	Hekman, A., et al., Immunotherapy, <i>The Netherlands Cancer Institute Amsterdam Annual Report</i> , pp. 47-48 (1993)		
	Lipton, J.M., et al., Distribution of B1, calla, $\beta$ 2 microglobulin and Ia on hematopoietic progenitors and hematopoiesis supporting cells (HSC) in short and long-term cultures, <i>Blood</i> , 60(5) (Suppl. 1):170a (Abstract 609) (1982)		
	Kaminski, M.G. et al., "Radioimmunotherapy of B-cell lymphoma with [ <sup>131</sup> I] anti-B1 (anti-CD20) antibody, <i>NEJM</i> 329/7 (1993).		
	Liu, A.Y. et al., Production of a Mouse-Human Chimeric Monoclonal Antibody to CD20 with Potent Fc-Dependent Biologic Activity. <i>J. Immun.</i> 139/10:3521-3526 (1987).		
	Marx, Antibodies made to order, <i>Science</i> 229 455 (August 1985).		
	Morrison, S.L., et al., Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains, <i>PNAS</i> 81:6851-6854 (November 1984).		
	Morrison, Transfectomas provide novel chimeric antibodies, <i>Science</i> 229:1202-1207 (September 1985).		
	Munro, Uses of chimaeric antibodies, <i>Nature</i> 312:597 (December 1984).		
	Nadler, L.M., et al., B cell origin of non-T cell acute lymphoblastic leukemia a model for discrete stages of neoplastic and normal pre-B cell differentiation, <i>J. Clin. Invest.</i> 74:332-340 (1984)		

W L

8/31/01

PAT-1449 12/9870048313v1

O P F  
V3  
2003  
PATENT LIBRARY  
SEARCHED  
INDEXED  
FILED

Nadler, L.M., et al., Anti-B1 monoclonal antibody and complement treatment in autologous bone-marrow transplantation for relapsed B-cell non-Hodgkin's lymphoma, <i>The Lancet</i> , Vol. II, pp. 427-431 (1984)			
Nadler, L.M., et al., Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen, <i>Cancer Research</i> , 40:3147-3154 (1980)			
Neuberger, M.S. et al., A hapten-specific chimaeric IgE antibody with human physiological effector function, <i>Nature</i> 314:268 (March 1985).			
Oettgen, H.C., et al., Further biochemical studies of the human B-cell differentiation antigens B1 and B2, <i>Hybridoma</i> , 2(1):17-28 (1983)			
Ozato, K., et al., Monoclonal antibodies to mouse MHC antigens III. Hybridoma antibodies reacting to antigens to the H-2 <sup>b</sup> haplotype reveal genetic control of isotype expression, <i>J. Immunology</i> , 126(1):317-321 (1981)			
Press et al., Monoclonal antibody 1F5 (Anti-CD20) serotherapy of human B cell lymphomas, <i>Blood</i> 69(2):584-591 (1987)			
Press, O.W. et al., "Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support." <i>New England Journal of Medicine</i> 329/17: 1219-12223 (1993).			
Press, O.W. et al., "Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody, <i>J. Clin. Onc.</i> 7/8:1027-1038 (1989)			
Reff, M., et al., Depletion of B cells <i>in vivo</i> by a chimeric mouse human monoclonal antibody to CD20, <i>J. Cellular Biochem., Suppl.</i> 17E:260 (Abstract T103) (1993)			
Reff, M., et al., Depletion of B cells <i>in vivo</i> by a chimeric mouse human monoclonal antibody to CD20, <i>Blood</i> , 83(2):435-445 (1994)			
Robertson, M.J., et al., Human bone marrow depleted of CD33-positive cells mediates delayed but durable reconstitution of hematopoiesis: Clinical trial of MY9 monoclonal antibody-purged autografts for the treatment of acute myeloid leukemia, <i>Blood</i> , 79(9):2229-2236 (1992)			
Robinson, R.D. et al., "Chimeric mouse-human anti-carcinoma antibodies that mediate different anti-tumor cell biological activities," <i>Hum. Antibod. Hybridomas</i> 2:84-93 (1991).			
Sahagan et al., A genetically engineered murine/human chimeric antibody retains specificity for human tumor-associated antigen, <i>J. Immunol.</i> 137:1066-1074 (1986).			
Scharff, M., The synthesis, assembly, and secretion of immunoglobulin: A biochemical and genetic approach, <i>Harvey Lectures</i> 69:125-143 (1974).			
Schlom J., et al., Advantage of dose fractionation in monoclonal antibody-targeted radioimmunotherapy, <i>J. Natl. Cancer Inst.</i> , 82(9):763-771 (1990)			
Shulman, M. et al., A better cell line for making hybridomas secreting specific antibodies, <i>Nature</i> 276:269 (1978).			
Smeland, E.B., et al., Activation of human B cells: Alternate options for initial triggering and effects of nonmitogenic concentrations of anti-IgM antibodies on resting and activated cells, <i>J. Immunology</i> , 138(10):3179-3184 (1987)			
Srivastava, S.C., et al., Progress in research on ligands, nuclides and techniques for labeling monoclonal antibodies, <i>Nucl. Med. Bio.</i> 18(6): 589-603 (1991).			
Sun, L.K. et al., Chimeric antibodies with 17-1A-derived variable and human constant regions, <i>Hybridoma</i> 5/1:517 (1986).			
Tan et al., A human-mouse chimeric immunoglobulin gene with a human variable region is expressed in mouse myeloma cells, <i>J. Immunol.</i> 135:8564 (November 1985).			
Tedder, T.F., et al., The B cell surface molecule B1 is functionally linked with B cell activation and differentiation, <i>J. Immunology</i> , 135(2):973-979 (1985)			
Urbaub, G. et al., Effect of gamma rays at the dihydrofolate reductase locus: deletions and inversions." <i>Som. Cell &amp; Mol. Gen.</i> 12/6:555-566 (1986).			
Valentine, M.A. et al., Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes, <i>J. Biol. Chem.</i> 264(19):11282-11287 (1989).			
Wessels, B.W., et al., Radionuclide selection and model absorbed dose calculations for radiolabeled tumor associated antibodies, <i>Med. Phys.</i> , 11(5):638-645 (1984)			

Examiner *[Signature]* Date Considered: 8/31/06

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.